Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Best Price” Exemption For Hospitals Is Test Of Discounts Under Medicare

Executive Summary

The Medicare Rx law's exemption of pharmaceuticals sold to disproportionate share hospitals from the Medicaid "best price" calculation will provide an early case study in the new pricing environment for drugs

You may also be interested in...



Safety Net Drug Pricing Program Growing Quickly After Eligibility Change

The Sec. 340B drug discount program is expanding rapidly because of changes in the Medicare Modernization Act

Safety Net Drug Pricing Program Growing Quickly After Eligibility Change

The Sec. 340B drug discount program is expanding rapidly because of changes in the Medicare Modernization Act

340B Drug Pricing Data Should Be Listed On Secure Website, IG Suggests

The Health Resources & Services Administration is considering developing a website to calculate drug discounts under the 340B program, following a recommendation by the HHS Inspector General

Related Content

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel